Kitasato symposium 2009: new prospects for cytokine inhibition.

about

Kitasato Symposium 2010: new prospects for cytokines.

P2860

Q42640325-22CF8664-9160-4530-AE51-F37307599CDE

P2860

Kitasato symposium 2009: new prospects for cytokine inhibition.

Item

http://www.wikidata.org/entity/Q42544274

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Kitasato symposium 2009: new prospects for cytokine inhibition.

@en

Kitasato symposium 2009: new prospects for cytokine inhibition.

@nl

type

Item

label

Kitasato symposium 2009: new prospects for cytokine inhibition.

@en

Kitasato symposium 2009: new prospects for cytokine inhibition.

@nl

prefLabel

Kitasato symposium 2009: new prospects for cytokine inhibition.

@en

Kitasato symposium 2009: new prospects for cytokine inhibition.

@nl

P1476

Kitasato symposium 2009: new prospects for cytokine inhibition.

@en

P2093

Kitasato Meeting Faculty*

http://www.w3.org/2001/XMLSchema#string

Peter E Lipsky

http://www.w3.org/2001/XMLSchema#string

Thomas Dörner

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning and characterization of IL-17B and IL-17C, two new members of the IL-17 cytokine family

IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1

Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies

SEROLOGICAL REACTIONS IN PNEUMONIA WITH A NON-PROTEIN SOMATIC FRACTION OF PNEUMOCOCCUS

Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease

Treatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis

Anti-cytokine therapy in chronic destructive arthritis

A novel cytokine receptor-ligand pair. Identification, molecular characterization, and in vivo immunomodulatory activity

Lymphotactin: a cytokine that represents a new class of chemokine

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

P2888

ar2857

P304

301

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/AR2857

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gerd-Rüdiger Burmester

P577

2009-12-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41000271

http://www.w3.org/2001/XMLSchema#string

P6179

1021506579

http://www.w3.org/2001/XMLSchema#string

P698

20067593

http://www.w3.org/2001/XMLSchema#string

P932

3003512

http://www.w3.org/2001/XMLSchema#string

Kitasato symposium 2009: new prospects for cytokine inhibition.

about

P2860

P2860

Kitasato symposium 2009: new prospects for cytokine inhibition.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P6179

P698

P932